Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer

Immunoassay for troponin I using a glassy carbon electrode modified with a hybrid film consisting of graphene and multiwalled carbon nanotubes and decorated with platinum nanoparticles

This article describes a bioelectrode for the determination of human cardiac troponin-I (cTnI). A glassy carbon electrode was coated with a hybrid film of graphene and multiwalled carbon nanotube (G-MWCNT) and modified with platinum nanoparticles (Pt NPs) that were capped with mercaptopropionic acid. The PtNPs were anchored on the G-MWCNT hybrid film via the cross-linker 1-pyrenemethylamine and subsequently functionalized with antibody against troponin (anti-cTnI). The bioelectrode was characterized by transmission electron microscopy, scanning electron microscopy, cyclic voltammetry, and electrochemical impedance spectroscopy. The performance of the immunoelectrode was investigated by electrochemical impedance spectroscopy, and response was fit to Randle's equivalent circuit model. The charge transfer resistance (R-et) at a.c. frequencies of < 1 Hz is found to be a viable sensing parameter. The dissociation constant of the immunoreaction between surface immobilized anti-cTnI and the analyte cTnI is 0.29 nM (with a Hill coefficient of 0.23), this indicating a negative cooperativity and high binding affinity of cTnI for anti-cTnI on the electrode surface. The EIS response is linear in the 1.0 pg mL(-1) to 10 ng mL(-1) concentration range, and the R-et sensitivity is 145.5 a"broken vertical bar cm(2) per decade